You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 271 No. 14, April 13, 1994 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contributions
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Comparison of Long-term Prognosis of Patients With AIDS Treated and Not Treated With Zidovudine

Jens D. Lundgren, MD, DSc; Andrew N. Phillips, PhD; Court Pedersen, MD, DSc; Nathan Clumeck, MD; Jose M. Gatell, MD, PhD; Anne M. Johnson, PhD; Bruno Ledergerber, PhD; Stefano Vella, MD; Jens O. Nielsen, MD, MSc; N. Clumeck; S. DeWit; B. Sommereijns; J. O. Nielsen; J. Lundgren; T. Nielsen; C. Pedersen; G. Jensen; P. Skinhøj; K. Bentsen; J. Gerstoft; M. Melbye; A. Ranki; S.-L. Valle; C. Katlama; P. Berlureau; M. Dietrich; S. Schwander; F.-D. Goebel; J. Kosmidis; G. Stergiou; T. Gouzia; A. Papadopoulos; D. Banhegyi; F. Mulcahy; I. Yust; Z. Ben-Ishai; Z. Bentwich; T. Sacks; S. Maayan; S. Vella; A. Chiesi; F. Ancarani; G. Scalise; A. Bertaggia; E. Francavilla; G. Calonghi; Arcispedale S. Maria Nuova; Reggio Emilia; A. Cargnel; M. Arlotti; R. Ciammarughi; A. Colomba; F. DeLalla; P. Fassio; A. Ferlini; F. Fiaccadori; G. Pasetti; F. Giannelli; W. Grillone; A Lazzarin; A. D'Arminio Monforte; E. Mignani; A. Nunnari; L. Ortona; G. Panichi; S. Pauluzzi; N. Piersantelli; S. Ranieri; P. Ricciardiello; B. Roscioli; M. Soranzo; R. Hemmer; S. Danner; D. Bloemkolk; F. Antunes; R. Proenca; J. González-Lahoz; L. Martinez-Blanco; B. Clotet; J. Gatell; E. Buira; J. Miró; P. Pehrson; R. Lüthy; B. Ledergerber; K. Olsson; M. Glauser; B. Hirschel; A. Johnson; S. Hawkes; A. Phillips; S. Barton; J. Morcinek; A. Pinching; D. Coleman; I. Gjprup; J. Lundgren; J. Nielsen; C. Nieport; C. Pedersen; L. Teglbjaerg; A. Thornval

JAMA. 1994;271(14):1088-1092.


Abstract

Objective.
—To determine the association between elapsed time since starting zidovudine and survival in patients with acquired immunodeficiency syndrome (AIDS).

Design.
—Inception cohort and observational study of patients treated and not treated with zidovudine.

Setting.
—Fifty-one centers in 17 European countries.

Patients.
—A total of 4484 patients diagnosed as having AIDS from 1979 to 1989 who survived their initial AIDS-defining event and who had not started zidovudine before AIDS diagnosis.

Main Outcome Measures.
—Use of zidovudine and mortality.

Results.
—Among patients who did not receive zidovudine, the death rate was approximately constant for the first 5 years after AIDS diagnosis. For patients treated with zidovudine, the death rate within the first year since starting zidovudine was markedly lower than for untreated patients who had developed AIDS at the same time (relative rate, 0.47; 95% confidence interval [CI] 0.42 to 0.51). For longer times since starting zidovudine, the association with reduced mortality rate was diminished, and for patients surviving more than 2 years since starting zidovudine, the death rate was greater than for untreated patients who had developed AIDS at the same time (relative rate, 1.35; 95% CI, 1.15 to 1.58). Adjustment for other prognostic factors failed to substantially affect this observation.

Conclusions.
—When initiated after the time of AIDS diagnosis, zidovudine was associated with improved prognosis but for no more than 2 years after starting therapy.

(JAMA. 1994;271:1088-1092)



Author Affiliations

AIDS in Europe Study Group; Belgium; Saint-Pierre Hospital, Brussels; Denmark; Hvidovre Hospital; Frederiksberg Hospital; Rigshospitalet, Copenhagen; Finland; University Central Hospital, Helsinki; France; Hospital de la PitiéSalpétrière, Paris; Germany; Bernhard-Nocht-Institut, Hamburg; Medizinische Poliklinik, Munich; Greece; Athens General Hospital; 1st IKA Hospital, Athens; Hungary; Postgraduate Medical School, Budapest; Ireland; St James's Hospital, Dublin; Israel; Ichilov Hospital, Tel Aviv; Rambam Medical Center; Haifa; Kaplan Hospital, Rehovot; Ha-; dassah University Hospital, Jerusalem; Italy; Istituto Superiore di Sanità, Rome; Universitá di Ancona; Osp Civile, Padua; Osp Sacco, Milan; Osp Infermi, Rimini; Osp Casa del Sole, Palermo; Osp Civile, Vicenza; OO.RR. di Bergamo; Osp Infermi, Faenza; Osp Riuniti, Parma; Osp Niguarda cà Granda, Milan; Osp Amedeo di Savoia, Turin; Osp L. Sacco, Milan; Osp S. Andrea, La Spezia; Patologia Medica Università, Catania; Università, Cattolica del Sacro Cuore, Rome; Universitá di Sassari; Policlinico Monteluce, Perugia; Osp Galliera, Genoa; Osp S. Maria delle Croci, Ravenna; Osp Maggiore, Novara; Osp S. Maria Maddalena, Trieste; Osp Amedeo di Savoia, Turin; Luxembourg; Centre Hospitalier, Luxembourg; Netherlands; Academisch Ziekenhuis bij de Universitet van Amsterdam; Portugal; Hospital Santa Maria; Hospital Curry Cabral, Lisbon; Spain; Instituto Carlos III, Madrid; Hospital Germans Trias i Pujol, Barcelona; Hospital Clinic I Provincial, Barcelona; Sweden; Karolinska Insitutet, Stockholm; Switzerland; Swiss HIV Cohort Study, Zurich; Centre Hospitalier Universitaire Vaudois, Lausanne; Hospital Cantonal Universitaire de Geneve, Geneva; United Kingdom; UCL Medical School; St Stephen's Clinic, Chelsea and Westminster Hospital; St Mary's Hospital; London

From the Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, Denmark (Drs Lundrgren, Pederson, and Nielsen); Academic Department of Genito-Urinary Medicine, University College of London (England) Medical School (Drs Phillips and Johnson); Division of Infectious Diseases, Saint-Pierre Hospital, Brussels, Belgium (Dr Clumeck); Infectious Disease Unit, Clinic i Provincial, Barcelona, Spain (Dr Gatell); Swiss HIV Cohort Study, Zurich, Switzerland (Dr Ledergerber); and Laboratory of Virology, Centro Operativo AIDS, Istituto Superiore di Sanità, Rome, Italy (Dr Vella).


Footnotes

A complete list of the members in the AIDS in Europe study group appears at the end of this article.

Reprint requests to Coordinating Centre for AIDS in Europe, Department of Infectious Diseases (144), Hvidovre Hospital, University of Copenhagen, DK-2650 Hvidovre, Denmark (Dr Lundgren).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Health and Federal Budgetary Effects of Increasing Access to Antiretroviral Medications for HIV by Expanding Medicaid
Kahn et al.
AJPH 2001;91:1464-1473.
ABSTRACT | FULL TEXT  

Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected Patients after the Introduction of Highly Active Antiretroviral Therapy
KIRK et al.
Am. J. Respir. Crit. Care Med. 2000;162:865-872.
ABSTRACT | FULL TEXT  

Impact of Protease Inhibitors and Other Antiretroviral Treatments on Acquired Immunodeficiency Syndrome Survival in San Francisco, California, 1987-1996
Schwarcz et al.
Am J Epidemiol 2000;152:178-185.
ABSTRACT | FULL TEXT  

Duration of the Survival Benefit of Zidovudine Therapy in HIV Infection
Moore et al.
Arch Intern Med 1996;156:1073-1077.
ABSTRACT  

Survival From Early, Intermediate, and Late Stages of HIV Infection
Enger et al.
JAMA 1996;275:1329-1334.
ABSTRACT  

Physicians' Experience with the Acquired Immunodeficiency Syndrome as a Factor in Patients' Survival
Kitahata et al.
NEJM 1996;334:701-707.
ABSTRACT | FULL TEXT  

Cost-effectiveness of HIV Screening in Acute Care Settings
Owens et al.
Arch Intern Med 1996;156:394-404.
ABSTRACT  

Race, Sex, Drug Use, and Progression of Human Immunodeficiency Virus Disease
Chaisson et al.
NEJM 1995;333:751-756.
ABSTRACT | FULL TEXT  

Changes in Survival Over Time After a First Episode of Pneumocystis carinii Pneumonia for European Patients With Acquired Immunodeficiency Syndrome
Lundgren et al.
Arch Intern Med 1995;155:822-828.
ABSTRACT  

Knowledge of Drugs for Myocardial Infarction: Generalists versus Specialists
Barry et al.
NEJM 1995;332:472-474.
FULL TEXT  

Generalists' Prudence May Lead to Better Outcomes-Reply
Markson et al.
Arch Intern Med 1995;155:336-337.
ABSTRACT  

The Efficacy of Zidovudine Is Time Limited
Berman and Wenglin
JAMA 1994;272:1001-1001.
ABSTRACT  

The Efficacy of Zidovudine Is Time Limited
Moore et al.
JAMA 1994;272:1001-1001.
ABSTRACT  

The Duration of Zidovudine Benefit in Persons With Asymptomatic HIV Infection: Prolonged Evaluation of Protocol 019 of the AIDS Clinical Trials Group
Volberding et al.
JAMA 1994;272:437-442.
ABSTRACT  

Use of CD4 lymphocyte count to predict long term survival free of AIDS after HIV infection
Phillips et al.
BMJ 1994;309:309-313.
ABSTRACT | FULL TEXT  

Slow Progress -- but Progress -- against HIV
Journal Watch Dermatology 1994;1994:15-15.
FULL TEXT  

SLOW PROGRESS -- BUT PROGRESS -- AGAINST HIV
JWatch General 1994;1994:2-2.
FULL TEXT  

Effectiveness of Zidovudine in Treatment of Advanced HIV Infection
Phair
JAMA 1994;271:1121-1122.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1994 American Medical Association. All Rights Reserved.